Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Fluocinolone acetonide intravitreal implant (Illuvien®)	TA301 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy TA590 - Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis TA953 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema
Fluorouracil injection	TA212 - Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer TA307 - Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy	For hospital use only
Foslevodopa–foscarbidopa (Produodopa®)	TA934: Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms
Fostamatinib (Tavlesse®)	TA835: Fostamatinib for treating refractory chronic immune thrombocytopenia
Fremanezumab (Ajovy®)	Fremanezumab for preventing migraine (TA764)
Fucibet cream	TA81 - Frequency of application of topical corticosteroids for atopic eczema	Steroid potency - potent
Fucidin H cream	TA81 - Frequency of application of topical corticosteroids for atopic eczema	Mild potency
Galantamine M/R capsules	TA217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease	Dementia drugs ESCA
Galantamine solution	TA217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease	Dementia drugs ESCA
Galantamine tablets	TA217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease	Dementia drugs ESCA

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.